Fycompa(perampanel)
Fycompa (perampanel) is a small molecule pharmaceutical. Perampanel was first approved as Fycompa on 2012-07-23. It is used to treat partial epilepsies, seizures, and tonic-clonic epilepsy in the USA. It has been approved in Europe to treat partial epilepsies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nervous system diseases | D009422 |
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
Fycompa
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Perampanel
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| FYCOMPA | Catalyst Pharmaceuticals | N-202834 RX | 2012-10-22 | 6 products, RLD, RS |
| FYCOMPA | Catalyst Pharmaceuticals | N-208277 RX | 2016-04-29 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| fycompa | New Drug Application | 2024-01-05 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| seizures | — | D012640 | G40.4 |
| partial epilepsies | EFO_0004263 | D004828 | — |
| tonic-clonic epilepsy | EFO_0007262 | D004830 | — |
Agency Specific
FDA
EMA
No data
HCPCS
No data
Clinical
Clinical Trials
104 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Seizures | D012640 | — | G40.4 | 1 | 9 | 9 | 4 | 10 | 32 |
| Epilepsy | D004827 | EFO_0000474 | G40.9 | 2 | 8 | 3 | 7 | 8 | 28 |
| Healthy volunteers/patients | — | — | — | 8 | — | — | 1 | — | 9 |
| Complex partial epilepsy | D017029 | EFO_1000877 | — | 2 | — | 1 | 1 | 2 | 6 |
| Tonic-clonic epilepsy | D004830 | EFO_0007262 | — | — | — | — | 1 | 4 | 5 |
| Partial epilepsies | D004828 | EFO_0004263 | — | — | — | — | 2 | — | 2 |
| Sleep initiation and maintenance disorders | D007319 | — | F51.01 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | 6 | 5 | — | — | 11 |
| Peripheral nervous system diseases | D010523 | — | G64 | — | 2 | 1 | — | — | 2 |
| Diabetic neuropathies | D003929 | EFO_1000783 | — | — | 2 | 2 | — | — | 2 |
| Lennox gastaut syndrome | D065768 | — | G40.81 | — | — | 1 | — | 1 | 2 |
| Neuralgia | D009437 | EFO_0009430 | — | — | 2 | 1 | — | — | 2 |
| Postherpetic neuralgia | D051474 | — | — | — | 2 | 1 | — | — | 2 |
| Syndrome | D013577 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Dyskinesias | D020820 | — | G24 | — | 2 | — | — | — | 2 |
| Epileptic syndromes | D000073376 | — | — | — | 1 | — | — | — | 1 |
| Glioma | D005910 | EFO_0000520 | — | 1 | 1 | — | — | — | 1 |
| Small fiber neuropathy | D000071075 | — | — | — | 1 | — | — | — | 1 |
| Migraine disorders | D008881 | EFO_0003821 | G43 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | — | — | — | 2 | 2 |
| Generalized epilepsy | D004829 | — | — | — | — | — | — | 1 | 1 |
| Amyotrophic lateral sclerosis | D000690 | EFO_0000253 | G12.21 | — | — | — | — | 1 | 1 |
| Motor neuron disease | D016472 | EFO_0003782 | G12.2 | — | — | — | — | 1 | 1 |
| Sclerosis | D012598 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Perampanel |
| INN | perampanel |
| Description | Perampanel is a member of the class of bipyridines that is 2,3'-bipyridin-6'-one substituted at positions 1' and 5' by phenyl and 2-cyanophenyl groups respectively. Used as an adjunctive therapy for the treatment of partial-onset seizures in patients with epilepsy. It has a role as an AMPA receptor antagonist and an anticonvulsant. It is a pyridone, a nitrile and a member of bipyridines. It is functionally related to a benzonitrile. |
| Classification | Small molecule |
| Drug class | ionotropic non-NMDA (N-methyl D-aspartate) glutamate receptors [AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor) and/or KA (kainite antagonist) receptors]: antagonists |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | N#Cc1ccccc1-c1cc(-c2ccccn2)cn(-c2ccccc2)c1=O |
Identifiers
| PDB | — |
| CAS-ID | 380917-97-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1214124 |
| ChEBI ID | 71013 |
| PubChem CID | 9924495 |
| DrugBank | DB08883 |
| UNII ID | H821664NPK (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Fycompa – Catalyst Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,887 documents
View more details
Safety
Black-box Warning
Black-box warning for: Fycompa
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
4,394 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use